研究疾病:
|
非酒精性脂肪性肝病
|
研究疾病代码:
|
|
Target disease:
|
NAFLD
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
以服用克癀胶囊前后基于CAP、ALT的临床有效率作为主要疗效指标,在全国多中心招募 NAFLD患者,评价克癀胶囊干预 NAFLD患者的安全性和有效性。
|
Objectives of Study:
|
Taking the clinical effective rate based on cap and ALT before and after taking Kelong capsule as the main efficacy index, NAFLD patients were recruited in multiple centers across the country to evaluate the safety and effectiveness of Kelong capsule in intervening NAFLD patients.
|
药物成份或治疗方案详述:
|
采用分层区组随机、多中心、双盲、平行对照临床试验的设计原则。克癀胶囊组与安慰剂组按1:1比例设计,每组50例,共计100例。治疗时间为12周,研究总体共计设置4次访视,筛查期1次,治疗期3次(基线0周、4周、12周)。以治疗12周后的临床有效率为研究终点。
|
Description for medicine or protocol of treatment in detail:
|
The design principle of stratified block randomized, multicenter, double-blind and parallel controlled clinical trial was adopted. Kelong capsule group and placebo group were designed in the ratio of 1:1, with 50 cases in each group, a total of 100 cases. The treatment time was 12 weeks. The overall study set up 4 visits, 1 screening period and 3 treatment periods (baseline 0 weeks, 4 weeks and 12 weeks). The end point of the study was the clinical effective rate after 12 weeks of treatment.
|
纳入标准:
|
(1)符合非酒精性脂肪性肝病诊断标准;
(2)符合中医湿热内蕴证诊断标准;
(3)年龄在 18~65岁之间;
(4)血清谷丙转氨酶(ALT)水平轻度升高,定义为ALT升高≤2.5倍正常上限;
(5)肝脏CAP≥259db/m(中度以上脂肪肝);
(6)知情同意,自愿受试,获得知情同意书过程应符合GCP规定。
|
Inclusion criteria
|
(1) Meet the diagnostic criteria of nonalcoholic fatty liver disease;
(2) Meet the diagnostic criteria of damp heat accumulation syndrome in traditional Chinese medicine;
(3) The age is between 18 and 65 years old;
(4) The level of serum alanine aminotransferase (ALT) increased slightly, which was defined as the increase of ALT ≤ 2.5 times the upper limit of normal;
(5) Liver cap ≥ 259db / M (moderate fatty liver);
(6) Informed consent, voluntary test, and the process of obtaining informed consent shall comply with the provisions of GCP.
|
排除标准:
|
(1) 合并有心脑血管、泌尿和造血系统等严重原发性疾病、恶性肿瘤、其他严重合并症或精神病患者;
(2) 合并1型糖尿病或未受控制的2型糖尿病,定义为糖化血红蛋白(HbA1c)≥9.5%,或入组前2月调整过降糖药物,或既往发生过严重低血糖事件;
(3) 严重肝功能损伤,定义为谷草转氨酶(AST)升高≥5倍正常上限,或总胆红素升高≥1.5倍正常上限;
(4) 严重肾功能不全,定义为血肌酐(SCR)≥178μmol/L,或肾小球滤过率(eGFR)<60;
(5) 合并甲状腺疾病,包括甲亢、甲减、亚临床甲减;
(6) 临床实验室及辅助检查提示存在肝硬化;
(7) 筛选时存在肝功能失代偿的临床证据;
(8) 筛选时实验室检查提示甲胎蛋白(AFP)>100ng/mL且影像学提示肝脏恶性占位可能者,或AFP持续3个月>100ng/mL;
(9) 妊娠期、哺乳期妇女及拒绝在整个研究过程中保持研究者所认可避孕措施的具有怀孕可能的妇女;
(10) 近3个月参加过其他临床试验者;
(11) 不能遵医嘱执行行为干预者;
(12) 怀疑有酒精、药物滥用病史者。
|
Exclusion criteria:
|
(1) Patients with serious primary diseases such as cardiovascular, cerebrovascular, urinary and hematopoietic systems, malignant tumors, other serious complications or psychosis;
(2) Patients with type 1 diabetes or uncontrolled type 2 diabetes were defined as glycosylated hemoglobin (HbA1c) ≥ 9.5%, or had adjusted hypoglycemic drugs 2 months before enrollment, or had serious hypoglycemic events in the past;
(3) Severe liver function injury is defined as the increase of aspartate aminotransferase (AST) ≥ 5 times the upper normal limit, or the increase of total bilirubin ≥ 1.5 times the upper normal limit;
(4) Severe renal insufficiency is defined as blood creatinine (SCR) ≥ 178 μ Mol / L, or glomerular filtration rate (EGFR) < 60;
(5) Combined with thyroid diseases, including hyperthyroidism, hypothyroidism and subclinical hypothyroidism;
(6) Clinical laboratory and auxiliary examinations suggest the presence of liver cirrhosis;
(7) Clinical evidence of decompensation of liver function at the time of screening;
(8) During screening, laboratory examination showed that alpha fetoprotein (AFP) > 100ng / ml, and imaging showed the possibility of malignant space occupying of liver, or AFP lasted for 3 months > 100ng / ml;
(9) Pregnant and lactating women and women who refuse to maintain the contraceptive measures approved by the researcher throughout the study;
(10) Those who have participated in other clinical trials in recent 3 months;
(11) Those who cannot follow the doctor's advice to perform behavioral intervention;
(12) Suspected to have a history of alcohol and drug abuse.
|
研究实施时间:
Study execute time:
|
从From
2022-06-01
至To
2024-05-31
|
征募观察对象时间:
Recruiting time:
|
从From
2022-06-30
至To
2024-06-01
|